Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Influenza, Human 2Lymphoma, Follicular 1Hematologic Neoplasms 1

Interventions

Influenza Vaccines 16trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine 2Vaccines 2Oseltamivir 2FluMist 2Cyclophosphamide 2ziprasidone 1vaxigrip 1thymoglobulin 1peginterferon alfa-2a 1influvac 1fludarabine 1baloxavir 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Starch 1Spironolactone 1Sevelamer 1SARS-CoV-2 inactivated vaccines 1Rocuronium 1Rituximab 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nivolumab 1Nifedipine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Influenza, Human × Oseltamivir × Clear all
NCT04712539 2026-02-11

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

M.D. Anderson Cancer Center

Phase 2 Recruiting
60 enrolled
Other hematologic neoplasm

Influenza, Human, Hematologic Neoplasms

NCT02108366 2019-10-21

Treatment of Severe Influenza A Infection

The University of Hong Kong

Phase 3 Completed
107 enrolled
Lymphoid

Influenza, Human, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡